FDA Approved: OPSYNVI — Supplemental Application (Actelion Pharmaceuticals US, Inc.)

View source ↗

Summary

FDA supplemental application for OPSYNVI (macitentan and tadalafil) by Actelion Pharmaceuticals US, Inc. seeks regulatory action on NDA218490. The filing likely…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• OPSYNVI (MACITENTAN AND TADALAFIL)

Snippet

SUPPL AP for OPSYNVI (MACITENTAN AND TADALAFIL)